US2020360345A1PendingUtilityA1

Compositions and methods for non-surgical treatment of ptosis

Assignee: VOOM LLCPriority: Mar 3, 2011Filed: Jun 4, 2020Published: Nov 19, 2020
Est. expiryMar 3, 2031(~4.6 yrs left)· nominal 20-yr term from priority
Inventors:Mark Silverberg
A61K 31/4174A61K 31/137A61P 27/02A61P 27/00A61P 21/04A61K 9/0048A61K 31/4164A61K 31/00A61P 43/00A61P 17/00A61P 21/00B65D 47/18A61K 31/135Y10S514/912
71
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition, to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.

Claims

exact text as granted — not AI-modified
1 - 40 . (canceled) 
     
     
         41 . A method of treating ptosis in a human patient, comprising administering oxymetazoline to the exterior surface of an eye of the patient, wherein the oxymetazoline is formulated as a pharmaceutical composition comprising about 0.05 to 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof, wherein the composition does not include a preservative, wherein the patient does not have an allergic ocular condition calling for the treatment of the eye with oxymetazoline, does not have eyelid swelling, and has not undergone refractive eye surgery. 
     
     
         42 . The method of  claim 41 , wherein the pharmaceutical composition comprises about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof. 
     
     
         43 . The method of  claim 41 , wherein the oxymetazoline or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt of oxymetazoline. 
     
     
         44 . The method of  claim 43 , wherein the pharmaceutically acceptable salt of oxymetazoline is oxymetazoline hydrochloride. 
     
     
         45 . The method of  claim 44 , wherein the pharmaceutical composition comprises about 0.1 weight percent oxymetazoline hydrochloride based on the oxymetazoline component alone. 
     
     
         46 . The method of  claim 41 , wherein administering the oxymetazoline comprises administering the pharmaceutical composition from a squeeze bottle or dropper capable of delivering a single drop with a volume of about 0.1 to 0.35 mL. 
     
     
         47 . The method of  claim 46 , wherein the pharmaceutical composition comprises about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof. 
     
     
         48 . The method of  claim 46 , wherein administering the oxymetazoline further comprises providing a kit comprising the squeeze bottle or dropper and instructional materials directing administration of the pharmaceutical composition in a method for treating ptosis in a human patient. 
     
     
         49 . The method of  claim 48 , wherein the pharmaceutical composition comprises about 0.1 weight percent oxymetazoline or a pharmaceutically acceptable salt thereof. 
     
     
         50 . The method of  claim 46 , wherein the instructional materials direct administration of the pharmaceutical formulation as a single drop. 
     
     
         51 . The method of  claim 41 , wherein the pharmaceutical composition further comprises a lubricant. 
     
     
         52 . The method of  claim 51 , wherein the lubricant is selected from artificial tears, white petrolatum, and mineral oil. 
     
     
         53 . The method of  claim 41 , wherein the pharmaceutical composition further comprises a tear substitute. 
     
     
         54 . The method of  claim 53 , wherein the tear substitute is selected from polyols, cellulose derivatives, dextrans, water soluble proteins, carbomers, and gums. 
     
     
         55 . The method of  claim 54 , wherein the tear substitute is a cellulose derivative. 
     
     
         56 . The method of  claim 55 , wherein the tear substitute is hypromellose. 
     
     
         57 . The method of  claim 46 , wherein the squeeze bottle or dropper is a single-dose product.

Join the waitlist — get patent alerts

Track US2020360345A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.